A visual description is not yet a diagnosis
Dark patches, post-acne marks and isolated spots can lead people to the same product aisle. AAD explains that a dermatologist may use examination and specialized light or magnification to assess melasma, and sometimes investigate another possible condition.[source]
A website cannot make that distinction from a person’s choice of search term. If the diagnosis is uncertain, the first useful question is what the pigment change represents, not which cream advertises the highest strength.
Bring the pattern and timeline to the visit
Describe when the change appeared, whether it followed inflammation or a new product, and what has already been tried. Include relevant medications and pregnancy history without stopping a medicine on your own.
That history can help the clinician decide whether a pigment-focused treatment is appropriate and whether an examination is needed. A generic claim that a cream addresses dark spots does not settle those questions.
Match the treatment’s scope to the actual concern
TRI-LUMA’s labeling is specifically about short-term treatment of moderate to severe facial melasma, with stated limits for other pigmentation conditions. Custom telehealth formulas and retail cosmetics have different descriptions and evidence.[source]
Once the concern is identified, compare the exact active ingredients, treatment window and follow-up. The five product reviews on this site are organized to support that conversation. They should not turn a broad cosmetic category into a diagnosis or imply that all visible discoloration benefits from the same intervention.
A retail serum does not settle the diagnosis
The new SkinCeuticals and Eucerin reviews widen the choice of formulas, but their dark-spot positioning should not turn every pigment change into melasma. A shared ingredient or cosmetic goal does not establish that the underlying concern is the same.
Ask which condition is being treated and which outcome would count as improvement. That gives the clinician and reader a clearer basis for interpreting a study about brown patches, post-blemish marks or overall tone. The retail-serum guide follows those distinctions through the evidence and budget.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- AAD: melasma diagnosis and treatmentAAD guidance rechecked October 10, 2026. · Checked October 10, 2026
- DailyMed: current TRI-LUMA prescribing informationGalderma drug labeling; current accessible version checked October 8, 2026 · Checked October 8, 2026